IVC and Lung Ultrasound B-lines Guided Decongestion in Critically Ill ESKD Patients With Heart Fa… (NCT06373575) | Clinical Trial Compass
UnknownNot Applicable
IVC and Lung Ultrasound B-lines Guided Decongestion in Critically Ill ESKD Patients With Heart Failure
China40 participantsStarted 2024-05-01
Plain-language summary
The objectives of this trial are to determine whether, in critically ill ESKD patients randomization to fluid removal guided by lung and inferior vena cava ultrasound, compared to standard care, leads to Improved pulmonary congestion (primary outcome); and safety (secondary outcome) in the short-term.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. patients meet the diagnostic criteria for end-stage renal disease;
✓. indications that the patient may be experiencing signs and/or symptoms of heart failure, and based on the serum N-terminal pro-brain natriuretic peptide level of greater than 11,215. 2 ng/L;
✓. patients may require prolonged intermittent renal replacement therapy due to volume overload;
✓. patients ≥18 yo and ≤80 yo;
✓. either the patient or a family member signs the informed consent;
✓. patients will undergo at least two sessions of prolonged hemodialysis.
Exclusion criteria
✕. history of malignancy or psychiatric disease;
✕. patients with a history of congenital heart disease or hypertrophic cardiomyopathy;
✕. coagulation abnormalities, intracranial, visceral or gastrointestinal bleeding in the past 3 months, or contraindications to heparin anticoagulation;
✕. The duration of prolonged hemodialysis \<8 hours;
✕. Ultrasound unable to monitor the inferior vena cava, or can't access the date;
✕. Pregnancy;
✕. Patients with severe respiratory failure;
What they're measuring
1
Improvement in pulmonary congestion score
Timeframe: within 72 hours following randomization
2
Improvement in heart failure symptoms score
Timeframe: within 72 hours following randomization
Trial details
NCT IDNCT06373575
SponsorThe First Affiliated Hospital with Nanjing Medical University